NanoBio to Announce Key Immune Response Data for Influenza

ANN ARBOR, Mich. (April 23, 2009) — NanoBio Corp. announced today that it will present compelling new data highlighting key milestones in the development of its novel non-inflammatory nanoemulsion adjuvant platform technology at the National Foundation for Infectious Diseases (NFID) conference, April 27-29. The new data will be delivered in two presentations during the 12th Annual Conference on Vaccine Research in Baltimore, Maryland.

Following is the data presentation schedule:

Monday, April 27, 2009

Poster Presentation: #166, 10:00 AM – 11:30 AM
Nasal Administration of Nanoemulsion W80/5EC Adjuvanted Influenza Vaccine in Mice

Oral Presentation: #165, 3:30 PM – 5:00 PM
W80/5EC, A Nanoemulsion Adjuvant Provides Robust Anti-influenza Immunity in
Ferrets after a Single Immunization

About NanoBio’s Vaccine Platform
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against influenza, hepatitis B, RSV, HIV, cancer, anthrax, smallpox and other diseases. The NanoStat™ platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

NanoBio Corp. announced earlier this week that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.

About NanoBio
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.